High-mobility group (HMG) proteins are nonhistone nuclear proteins that play an important role in the regulation of chromatin structure and function. HMGI-C and HMGI(Y) are members of the HMGI family of HMG proteins, and their expression in adult tissues generally correlates with malignant tumor phenotypes. However, HMGI-C and HMGI(Y) dysregulation as a result of specific rearrangements involving 12q15 and 6p21, the respective chromosomal sites in which the HMGI-C and HMGI(Y) genes are located, is also identified in a variety of common benign mesenchymal tumors, such as lipomas and uterine leiomyomata. The general prevalence of HMGI-C and HMGI(Y) protein expression and its correlation with chromosomal alterations in these benign tumors are unknown. We analyzed 95 human tumors (20 lipomas, 21 pulmonary chondroid hamartomas, 26 uterine leiomyomata, and 28 endometrial polyps) representing a selection of the benign lesions in which karyotypic alterations involving the chromosomal regions 12q15 and 6p21 are frequently detected. All cases were successfully karyotyped and some of them analyzed by fluorescent in situ hybridization with probes spanning the HMGI-C and HMGI(Y) genes. The results of this study demonstrate that expression of HMGI-C or HMGI(Y) is a common occurrence in lipomas, pulmonary chondroid hamartomas, leiomyomata, and endometrial polyps; that it correlates with 12q15 and 6p21 chromosomal alterations (p Ͻ 0.001); and that it is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. The expression pattern and cellular localization of the immunoreactivity support the view that in biphasic lesions composed of a mixture of both stromal and epithelial cells, such as pulmonary chondroid hamartoma and endometrial polyps, the mesenchymal component is the site of the HMGI genetic alterations. (Lab Invest 2000, 80:359-369).
T he chromosomal regions 12q15 and 6p21 are frequently involved in the karyotypic alterations observed in a variety of benign human tumors, such as pulmonary chondroid hamartomas, lipomas, uterine leiomyomata, and endometrial polyps (Mitelman, 1998) . All of these are characterized by abnormal proliferation of mesenchymal cells and include some of the most common tumors occurring in our species (eg, lipoma and uterine leiomyoma). HMGI-C and HMGI(Y) are members of the HMGI family of "highmobility group" (HMG) proteins. They act as architectural transcription factors and are commonly expressed in embryonal cells Hirning-Folz et al, 1998) , in transformed cells with a malignant phenotype Bussemakers et al, 1991; Giancotti et al, 1987; 1989; Ram et al, 1993) , and in a variety of human cancers (Bandiera et al, 1998; Chiappetta et al, 1995; 1998; Fedele et al, 1996; Rogalla et al, 1997; Rommel et al, 1997; Tamimi et al, 1993) . HMGI-C and HMGI(Y) genes are located at 12q15 and 6p21 (Friedmann et al, 1993) , respectively. HMGI-C is not expressed in normal adult mouse (Manfioletti et al, 1991) or human tissues (Rogalla et al, 1996) , whereas HMGI(Y) is only expressed at very low levels .
Given the association of HMGI-C and HMGI(Y) with a transformed malignant phenotype, the recent identification of HMGI-C and HMGI(Y) as candidate tumor genes for a variety of benign neoplasms with specific chromosomal alterations at 12q15 and 6p21 came somewhat as a surprise. HMGI-C dysregulation has been shown in lipomas (Ashar et al, 1995; Schoenmakers et al, 1995) , pulmonary chondroid hamartomas (Kazmierczak et al, 1996b) , uterine leiomyomas (Kazmierczak et al, 1995a; Schoenberg Fejzo et al, 1996) , endometrial polyps Wanschura et al, 1997) , and in other tumor types featuring 12q15 karyotypic abnormalities (Kazmierczak et al, 1995b; Staats et al, 1996) . These tumors, moreover, often feature distinct subsets with 6p21 chromosomal changes, and disregulated HMGI(Y) expression has also been identified in lipomas (Tkachenko et al, 1997) , pulmonary chondroid hamartomas (Xiao et al, 1997) , uterine leiomyoma (Williams et al, 1997) , and endometrial polyps . Despite this experimental evidence linking chromosomal rearrangements involving 12q15 and 6p21 with HMGI-C and HMGI(Y) dysregulation, it is unclear however, whether these chromosomal changes are as a rule associated with increased levels of HMGI-C or HMGI(Y) proteins and whether there is a definite correlation between aberrant protein expression and the cytogenetic abnormalities. Previous results have suggested such a correlation for adipose tissue tumors (Tallini et al, 1997) . We have therefore furthered our investigations to include the analysis of additional cases of lipomas as well as of a series of pulmonary chondroid hamartomas and of uterine leiomyomas. All tumors were investigated by conventional cytogenetic analysis and some of them by fluorescence in situ hybridization (FISH) with probes for HMGI-C and HMGI(Y) (Kazmierczak et al, 1996c; . In the absence of suitable samples for Western blot analysis, immunohistochemistry was selected to detect HMGI-C and HMGI(Y) protein expression because it offers the advantage of in situ tissue discrimination. The objectives of the study were to determine for lipomas, pulmonary chondroid hamartomas, uterine leiomyomas, and endometrial polyps: a) the prevalence of HMGI-C and HMGI(Y) protein (over)expression in these tumors; b) the existence of any correlation with the cytogenetic changes; and c) the tissue localization of the cells exhibiting (over)expression.
Results
The data in Tables 1-4 allow for a correlation of immunohistochemical reactivity for HMGI-C and HMGI(Y) with cytogenetic and FISH analysis in the various individual tumors. Overall, HMGI-C and HMGI(Y) immunoreactivity ( Fig. 1) 
Lipoma
In lipomas immunohistochemical reactivity was visualized in the adipocyte nuclei (Fig. 1a) . As shown in Table 1 , of the nine cases with cytogenetic alterations at 12q15, eight were positive for HMGI-C. FISH confirmed rearrangement of the HMGI-C gene in five cases. The two cases with karyotypic alterations at 6p21 were positive for HMGI(Y), including one case featuring both 12q15 and 6p21 karyotypic alterations (19L). In the latter case, no significant HMGI-C reactivity was seen. Of the seven cases with normal karyotype, two were positive for HMGI-C, and one was positive for HMGI(Y) by immunohistochemistry. 
Pulmonary Chondroid Hamartoma
In pulmonary chondroid hamartomas, immunohistochemical reactivity for either HMGI-C or HMGI(Y) was predominantly located in the nuclei of adipocytes, cartilage cells, or stromal cells (Fig. 1c) . However, there were occasional positive cells also in the epithelial component of the tumor, regardless of whether the case was eventually scored as positive or negative for HMGI-C or HMGI(Y). Focal immunoreactivity for HMGI-C and HMGI(Y), respectively, was seen in the pneumocytes of one of seven and two of seven samples of non-neoplastic lung tissue used as controls. As shown in Table 2 , of the 14 cases with karyotypic alterations at 12q15 and/or HMGI-C rearrangement detected by FISH, 11 were positive for HMGI-C by immunohistochemistry, including four cases that co-expressed both HMGI-C and HMGI(Y).
The remaining three cases were negative for HMGI-C 
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Uterine Leiomyoma
In leiomyomas immunohistochemical reactivity was seen in the nuclei of smooth muscle cells (Fig. 1e ). Focal immunoreactivity, particularly for HMGI(Y), was observed in rare nuclei of myometrial cells in the areas surrounding the leiomyoma. As shown in Table 3 , of the 11 cases with karyotypic alterations at 12q15 and/or HMGI-C rearrangement detected by FISH, 10 were positive for HMGI-C by immunohistochemistry, including one case which co-expressed both HMGI-C and HMGI(Y). 
Endometrial Polyp
In endometrial polyps immunohistochemical reactivity for either HMGI-C or HMGI(Y) was predominantly located in the nuclei of stromal cells (Fig. 1g) . However, positive cells for HMGI(Y) and less frequently for HMGI-C were commonly observed in the nuclei of the endometrial glands both inside and outside of the polyp and regardless of whether the case was eventually scored as positive or negative for HMGI-C or HMGI(Y). At least focal HMGI-C and HMGI(Y) immunoreactivity was observed in 3 of 10 and 7 of 10 endometrial control samples of normal karyotype, respectively. HMGI protein expression was usually seen in those endometrial glands exhibiting proliferative features. As shown in Table 4 , of the eight cases with karyotypic alterations at 12q15 and/or HMGI-C rearrangement detected by FISH, seven were positive for HMGI-C by immunohistochemistry, including two cases that co-expressed HMGI-C and HMGI(Y). 
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Discussion
The molecular changes underlying HMGI-C and HMGI(Y) gene dysregulation in benign tumors seem to be consistent with two general mechanisms already identified in other tumor types. These involve either intragenic rearrangements with chimeric fusion products between two different genes, which are juxtaposed as a consequence of the chromosomal translocation, or rearrangements with breakpoints located outside the coding region of the gene, which result in transcriptional activation due to the fusion of enhancer sequences in the translocation partners (Rabbitts, 1994) . Several chimeric mRNAs involving HMGI-C have been identified, such as HMGI-C/LPP (lipoma preferred partner) in lipomas and pulmonary chondroid hamartomas with the t(3;12) (Petit et al, 1996) , HMGI-C/ALDH2 (mitochondrial aldehyde dehydrogenase) in a uterine leiomyoma with a paracentric inversion of chromosome 12 (Kazmierczak et al, 1995a) , and HMGI-C/RTVLH (retrovirus like human sequences) in pulmonary chondroid hamartomas and uterine leiomyomas with seemingly normal karyotypes (Kazmierczak et al, 1996a) . All of these rearrangements involve the large (140 kb) third intron of HMGI-C and result in the loss of the 3Ј portion of the gene coding for the protein-binding domains of HMGI-C. It is important to recognize that even if the fusion products listed above are in frame, some of the rearranged genes contribute very few amino acids to the chimeric products (Kazmierczak et al, 1995a) . It has therefore been suggested that the minimal requirement for tumorigenesis would be HMGI-C activation due to rearrangements, which leave intact at least exons 1-3 of the gene that code for the AT hook domains (Kazmierczak et al, 1996b; Rogalla et al, 1996) . Breakpoints outside (usually upstream) of the coding region of HMGI-C have also been identified with chromosome aberrations mapped to the HMGI-C locus (Kazmierczak et al, 1999 ; Schoenberg Fejzo et a, Nuclear reactivity for HMGI-C in the neoplastic adipocytes of a lipoma (case 17L); t(2;12)(q35;q15) was identified in the tumor karyotype, FISH analysis was not performed. b, The corresponding immunohistochemical stain for HMGI(Y) is negative (case 17L). c, Positive nuclear reactivity for HMGI(Y) in the mesenchymal cells of a pulmonary chondroid hamartoma (case 11P); t(6;10)(p21.3;q22.3) was identified in the tumor karyotype (Fig. 2d) , FISH analysis results are illustrated in Figure  2c and are compatible with HMGI(Y) gene rearrangement. d, The corresponding immunohistochemical stain for HMGI(Y) is negative (case 11P). e, Nuclear reactivity for HMGI(Y) in the neoplastic smooth muscle cells of an uterine leiomyoma (case 1M); t(6;14)(p21;q24) was identified in the tumor karyotype; FISH analysis results are compatible with HMGI(Y) gene rearrangement. f, The corresponding immunohistochemical stain for HMGI-C is negative (case 1M). g, Nuclear reactivity for HMGI-C in the stromal component of an endometrial polyp (case 10E); t(12;14)(q15;q24 -25) was identified in the tumor karyotype; FISH analysis results are compatible with HMGI-C gene rearrangement. The corresponding immunohistochemical stain for HMGI(Y) is negative (case 10E).
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al Wanschura et al, 1996) . HMGI-C amplification has been recently documented in a benign endometrial polyp characterized cytogenetically by double minute chromosomes . In the tumors with HMGI(Y) rearrangement, most of the breakpoints are located outside the coding portions of the gene (usually downstream) (Kazmierczak et al, 1996c; Tkachenko et al, 1997; Williams et al, 1997) . This may indicate that the replacement of negative regulatory sequences by enhancers from the translocation partners is the likely molecular mechanism for HMGI(Y) dysregulation . At variance with what is observed for HMGI-C, only one chimeric fusion transcript due to an intragenic rearrangement of HMGI(Y) has been identified to date (Xiao et al, 1997) . Despite the abundant evidence for HMGI-C and HMGI(Y) dysregulation in the benign tumors discussed above, few studies have documented whether rearrangement of the HMGI genes actually results in aberrant (over)expression of the corresponding protein Tallini et al, 1997; Williams et al, 1997) . Our study clearly demonstrates that HMGI-C and HMGI(Y) are commonly expressed in lipomas, pulmonary chondroid hamartomas, uterine leiomyomas, and endometrial polyps. Both genes are not expressed at any significant level in mature cells Gattas et al, 1999; Manfioletti et al, 1991; Rogalla et al, 1996) , and it has been shown that proliferating non-transformed cells express markedly lower HMGI(Y) (Bussemakers et al, 1991; Ram et al, 1993) or HMGI-C ) levels compared with their transformed counterpart. However, both proteins were commonly detected in the tumors analyzed in this study, all are benign and slow growing, while no significant immunoreactivity was seen in the perilesional portions of normal tissue. In addition, the immunohistochemical detection of HMGI-C and HMGI(Y) remarkably correlated with the type of alteration detected by conventional chromosome analysis at 12q15 and 6p21 and/or by FISH using probes for HMGI-C and HMGI(Y). The association between immunohistochemical results and genetic changes is significant both in general terms for the entire pool of cases analyzed as well as within each tumor category. This correlation indicates that the aberrant (over)expression of HMGI-C and HMGI(Y) is not simply the result of increased cellular proliferation but that it is related to the specific molecular changes that accompany the chromosomal rear- a, Localization of a pool of cosmids (RM 133, RM 76, RM 53) spanning the HMGI-C gene in a metaphase spread of a pulmonary chondroid hamartoma (case 12P). Signals are seen on the normal chromosome 12, and the derivative chromosomes 12 and 16 (arrows). b, GTG banding was performed on the same metaphase spread prior to FISH. c, Localization of PAC 8603 spanning the breakpoint region 6p21.3 and containing the complete HMGI(Y) sequence in a metaphase spread of a pulmonary chondroid hamartoma (case 11P). Signals are seen on the normal chromosome 6, and the derivative chromosomes 6 and 10 (arrows). d, GTG banding of the same metaphase spread was performed prior to FISH.
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Laboratory Investigation • March 2000 • Volume 80 • Number 3 rangement. It also shows that the majority of the rearrangements are in frame and that the resulting mRNAs are translated into detectable protein levels, thus supporting a possible role of HMGI-C and HMGI(Y) in tumor growth. FISH analysis with microclone probes spanning the HMGI-C and HMGI(Y) loci allows the discrimination between cases with intragenic breaks and those with breakpoints located outside of the gene, either upstream or downstream Kazmierczak et al, 1996b; Schoenmakers et al, 1995) . Although measurements of the precise amount of tissue immunoreactivity could not be reliably estimated, comparison with the immunohistochemical results indicates that HMGI-C or HMGI(Y) expression is not significantly different regardless of whether the breakpoints are located inside or outside (5Ј-or 3Ј-) of the gene (data not shown).
Genetic HMGI alterations were not accompanied by detectable HMGI-C and HMGI(Y) immunoreactivity in approximately 5-10% of the tumors. This may be explained by an increase in protein expression below the sensitivity of the immunohistochemical analysis, by the presence of a fusion protein too abnormal to be recognized with the antibodies used for the study, by sample bias, or by a combination of the above. However, tissue immunoreactivity for HMGI-C and HMGI(Y) was observed in approximately 20% of the cases lacking cytogenetic evidence of 12q15 or 6p21, possibly due to defective cell growth for karyotyping or by the presence of cryptic rearrangements, as previously shown in pulmonary chondroid hamartomas (Kazmierczak et al, 1996a) , uterine leiomyomata (Williams et al, 1997) , and endometrial polyps (Wanschura et al, 1997) . Analogous to what was observed for Cyclin D1 expression in mantle cell lymphoma (de Boer et al, 1995; , gene expression as detected by immunohistochemistry may be more sensitive than cytogenetics as a marker for gene dysregulation. In addition to high sensitivity, immunohistochemistry offers the advantage of allowing in situ tissue discrimination with the possibility of identifying the specific cell types in which HMGI-C and HMGI(Y) are aberrantly expressed. This is particularly relevant because lesions such as endometrial polyps and pulmonary chondroid hamartomas include both epithelial as well as mesenchymal components. In both tumor types it was the immunoreactivity observed in the mesenchymal cells that consistently paralleled the cytogenetic findings, thus confirming previous observations on the pivotal role of stromal cells in the development of pulmonary chondroid hamartomas (Fletcher et al, 1992a) and endometrial polyps (Fletcher et al, 1992b) . Distinct nuclear HMGI protein immunoreactivity was observed in some of the endometrial glands as well as in occasional epithelial cells in pulmonary chondroid hamartomas. HMGI protein immunoreactivity in these cells did not correlate with chromosomal alterations and may represent a nonspecific result of increased proliferation or a response to microenvironmental influences (Gattas et al, 1999) . At least focal HMGI-C and HMGI(Y) immunoreactivity was observed in endometrial control samples in which immunohistochemical reactivity was associated with endometrial glands exhibiting proliferative features. Interestingly, HMGI-C was detected by RTPCR in 2 of 10 myometrial samples in the study by Rogalla et al (1996) and, although this may have been due to the presence of leiomyomata too small to be identified at the time of tissue collection (Rogalla et al, 1996) , it can not be excluded that the HMGI-C positivity was in fact due to contamination of the specimens by proliferative endometrium. Focal HMGI protein immunoreactivity was also seen in the pneumocytes of non-neoplastic lung tissue controls, a finding that is consistent with the RTPCR detection of HMGI-C in normal adult lung samples (Gattas et al, 1999) . These observations indicate that although both HMGI-C and HMGI(Y) are generally not expressed at any significant level in normal adult tissues Rogalla et al, 1996; Gattas et al, 1999) , their expression may be upregulated, presumably as a result of non-neoplastic cellular proliferation or microenvironmental factors. Although low level expression of HMGI(Y) in adult tissue has been documented , these findings require further study, particularly in the light of recent observations reporting increased HMGI-C levels in normal in vitro cultured cells (Gattas et al, 1999) .
In conclusion, this study shows that expression of HMGI-C and HMGI(Y) is a common occurrence in those benign human tumors carrying chromosome abnormalities at 12q15 and 6p21 and that their expression pattern is compatible with the postulated rearrangements involving HMGI-C and HMGI(Y) genes. It also supports the view that in biphasic lesions composed of a mixture of both stromal and epithelial cells, the mesenchymal component is the site of the HMGI genetic alterations and abnormal gene expression. Further investigation of disregulated HMGI expression in cytogenetically abnormal human tumors may contribute to a better understanding of the role that is played by HMGI proteins in normal and abnormal cellular growth and development.
Materials and Methods

Selection of Cases
A group of 95 human tumors was analyzed. They constitute a representative sample of the benign lesions in which karyotypic rearrangements at 6p21 and/or 12q15 are commonly detected (Mitelman, 1998) and included 21 pulmonary chondroid hamartomas, 20 lipomas, 26 uterine leiomyomata, and 28 endometrial polyps. These tumors were chosen to include lesions with 6p21 or 12q15 rearrangements as well as cases with seemingly normal karyotypes and cases with alterations not involving 6p21 or 12q15 for each tumor type.
Cytogenetic and Molecular Cytogenetic Analysis
Conventional chromosomal analysis was performed after short-term culture by G-banding in the cytoge- Tallini et al netic laboratories of the universities of Leuven (Belgium) (43 cases), Bremen (Germany) (21 cases), and Cagliari (Italy) (31 cases). All tumors were successfully karyotyped and included lesions with 6p21 (n ϭ 17) or 12q15 alterations (n ϭ 33), karyotypic alterations not involving 6p21 or 12q15 (n ϭ 13), or a normal karyotype (n ϭ 32). FISH was performed after GTG banding of the same metaphase spreads according to previously published procedures (Kievits et al, 1992) . Metaphases were hybridized with a pool of different cosmids spanning over the breakpoint region 12q15 and flanking the third intron of HMGI-C Kazmierczak et al, 1996b) and with PAC clones containing the HMGI(Y) gene mapped at 6p21.2 (Kazmierczak et al, 1996c) . In translocations affecting HMGI-C or HMGI(Y), hybridization signals were observed on the derivative chromosomes and/or on the translocation partners of chromosomes 12 or 6, respectively. In the case of peri-or paracentric inversions of chromosomes 12 or 6, split signals on the short and the long arm or a double signal on one arm was observed. Cytogenetic and FISH analysis data were compiled independently of the immunohistochemical results and, for many of the cases, have been previously reported (Dal Cin et al, 1995; Kazmierczak et al, 1996b; .
Immunohistochemistry
Representative routinely processed paraffinembedded blocks from the selected cases were obtained from the pathology laboratories of the medical centers in Leuven (Belgium), Eindhoven (Holland), Bremen (Germany), and Cagliari (Italy). Histology sections were cut and immunostained according to established protocols using an avidin-biotinylated peroxidase complex (ABC) technique previously described (Tallini et al, 1997) . The HMGI-C antibodies were raised in rabbits against the recombinant murine HMGI-C protein, and, because of the high degree of homology between mouse and human HMGI-C, they also recognize the human protein. The HMGI-C antibodies were used at a 1:400 dilution. Before incubation, histology sections were pretreated with 0.6 mg Pronase (Sigma, St. Louis, Missouri) for 5Ј (Tallini et al, 1997) . The antibodies against HMGI(Y) were developed against a HMGI(Y)-specific synthetic peptide corresponding to the NH 2 Ϫ terminal portion of the molecule (Chiappetta et al, 1995) . They were used at a 1:100 dilution. For optimal results, the concentration of the HMGI-C and HMGI(Y) antibodies in a minority of cases had to be tailored to take into account differences in tissue processing and preservation methods among the different pathology departments. No significant cross-reactivity was observed between HMGI(Y) and HMGI-C. Negative controls were performed by omitting the primary antibody or by incubating the histology sections with an unrelated nuclear antibody against Human Papilloma Virus (Dako Corporation, Glostrup, Denmark), according to the specifications provided by the manufacturer. Examination of perilesional normal tissue provided a built in negative control for most of the cases analyzed. In addition, 10 samples of previously karyotyped normal endometrium as well as seven samples of non-neoplastic lung tissue were also investigated. Immunohistochemistry results were analyzed without knowledge of the cytogenetic data. Only those cases in which there was positive nuclear staining in more than 10% of the tumor cells were scored as positive. The significance of the immunohistochemical findings was statistically evaluated. The Fisher's Exact test was used to determine the association between HMGI-C or HMGI(Y) reactivity and 6p21 or 12q13-15.
